Carmot Therapeutics, Inc. is a biotech company focused on the discovery of innovative drugs for the treatment of metabolic diseases, cancer, and inflammation. Carmot’s vision is to become a leader in drug discovery by unlocking novel therapeutic target space not currently accessible to conventional small molecule technologies.
Chemotype Evolution, Carmot’s proprietary technology, enables the rapid identification of novel drugs through an evolutionary lead-identification paradigm, which has empowered the discovery of breakthrough therapeutics currently in the pipeline.
Founded in 2008 by Drs. Stig K. Hansen and Daniel A. Erlanson, Carmot has built and optimized this powerful platform to identify superior drugs for validated targets with significant market potential such as GLP-1R for Type 2 diabetes and NEMO/IKK for cancer and inflammation, and which have been refractory to traditional discovery approaches.
Drug discovery is immensely expensive, and Carmot is aware of the challenges. Thus, the company intends to partner products with established pharmaceutical partners prior to commercialization, and in some cases prior to initiating clinical trials.
Carmot is located in the Mission Bay area of San Francisco, within an incubator network established by Fibrogen and the California Institute of Quantitative Biosciences (QB3) at UCSF. This is a vibrant and stimulating environment that attracts top talent and fosters innovation.
Far right image, above. Solimena Lab, Med. Fac., University of Technology, Dresden, Germany. Source